

OPPORTUNITY



- SAVING PATIENT LIVES...** 5 yr mortality of 2-Stage Revision greater than Breast or Prostate Cancer⁷
- SAVING PATIENT LIVELIHOOD, VOCATION...** reducing typical 3 – 12 months of disability and morbidity
- SAVING LIMBS...** reducing risk of amputation due to repeated treatment failures (average 10-50%)^{4,5}
- REDUCING SURGEON FRUSTRATION...** lack of confidence with three (3) current surgical options
- REDUCING FINANCIAL LIABILITY...** when failure occurs within global 90 day period, \$50-160k/patient⁶



NON-TARGETED ANTIBIOTIC DOSING VS TARGETED ANTIBIOTIC DOSING

Current administration methods are sub-therapeutic, unable to achieve biofilm eradication concentrations

Clinical research with cyclic, super-therapeutic concentrations proves superior outcomes w/o harm¹⁰



Currently, poor treatment of biofilm is the primary reason for persistent infection

US Economic Impact for treating Periprosthetic Joint Infection is \$1.6B (2020) and growing¹⁴

SAM \$980M in US³

For Joints, by 2024:


- 3.4M / yr Total US Primary Joints (hips & knees);
- 12.6M Americans with Total Joint Implants;
- Est: 141k / yr US Total Joint Infections^{1,2}

For Spine:


- 1.62M / yr US Instrumented Spinal Fusions¹²
- Est: ~45k / yr US Spinal infection¹³
- Death rate est ~ 20%¹³

LOCAL ANTIBIOTICS VIA SIMPLE, LOW COST IMPLANTED DELIVERY SYSTEM

Antibiotic Dispensing Spacer (replacement)



Remote Implanted Drug Delivery System



Simple, implanted pump & reservoir provides local delivery of available antibiotic to targeted location



Low cost implant is electromagnetically coupled and driven by an external Programmable Controller

LOWER TREATMENT COST, REDUCED MORBIDITY, REDUCE MORTALITY

At ForCast Ortho, we: * understand the combination regulatory pathway; * have established Intellectual Property with 2 issued patents to date; * have a strong advisory board of surgeons and biomedical experts; * have a strong team with over 100 (cumulative) years of experience in medical devices and implantable products; * >75% GM projected; * are accelerating our development progress toward clinical evaluation.
Come join us as we improve patient lives.

Better treatment can expand **Implant Retention**; NEJM estimates 60% of PJI cases are viable for I&D¹²

A potential Savings of \$96,500 / patient, over current 2-stage SOC¹¹